Verrica Pharmaceuticals Inc (VRCA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.30-1.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VRCA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Grow revenue and dispensed applicator units of YCANTH for molluscum contagiosum and prepare for expansion into common warts indication.
Stated as a priority in 2 of last 2 quarters. YCANTH dispensed applicator units grew approximately 46% year-over-year and 28% sequentially in Q2 2026, with product revenue increasing from $4.3 million in Q1 2026 to $5.1 million in Q2 2026. Management is delivering on expanding YCANTH sales and market penetration.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Demand for YCANTH continues to accelerate, with dispensed applicator units up 46% year-over-year and 28% sequentially.”
“Demand for YCANTH grew sharply during the first quarter, setting new records for dispensed applicator units.”
Progress enrollment and initiate trials for YCANTH to treat common warts, targeting topline data in mid-2027.
Stated as a priority in 2 of last 2 quarters. Management reports dosing the first patient in the second pivotal trial and achieving over 50% enrollment in the first trial of the Phase 3 common warts program, with topline data expected mid-2027. Progress matches management's stated clinical development timeline.
“First U.S. patient dosed in second pivotal trial (COVE-3) for common warts; topline data expected mid-2027.”
“Over 50% of targeted enrollment achieved in first trial (COVE-2) of global Phase 3 common warts program.”
Advance clinical development of VP-315 oncolytic peptide, including Phase 2 data presentation and Phase 3 readiness activities.
Stated as a priority in 2 of last 2 quarters. Management presented Phase 2 data showing potential abscopal effects for VP-315 and is advancing Phase 3 readiness. The clinical development is progressing as planned.
“Phase 2 data for VP-315 showed potential abscopal effect; continuing Phase 3 readiness activities.”
“Announced upcoming presentation of Phase 2 data for VP-315 at 2026 SID Annual Meeting.”
Extend cash runway into 2028 through operating plan and new $27.5 million credit facility.
Newly stated in 2026-Q2. Management announced a $27.5 million credit facility that could extend the cash runway into 2028 based on the current operating plan. This financial measure supports ongoing operations and development programs.
“New credit facility for up to $27.5 million extends cash runway into 2028 based on current operating plan.”
Pursue regulatory approval for YCANTH in Japan to unlock additional funding.
Over the trailing year it converted 0.87x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
21 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.